Evidence map›Paper›PMID 37662686›Full record

ArticleInternational journal of nanomedicine2023

Combined Dextran-Graft-Polyacrylamide/Zinc Oxide Nanocarrier for Effective Anticancer Therapy in vitro.

Vasyl Chumachenko, Pavlo Virych, Guochao Nie, Petro Virych, Oleg Yeshchenko, Pavlo Khort, Anton Tkachenko, Volodymyr Prokopiuk, Nataliia Lukianova, Taras Zadvornyi and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of nanomedicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 3 countries.

Vasyl ChumachenkoChemistry Department, Taras Shevchenko National University of Kyiv, Kyiv, Ukraine.
Pavlo VirychChemistry Department, Taras Shevchenko National University of Kyiv, Kyiv, Ukraine.ORCID 0000-0002-1463-1992
Guochao NieGuangxi Universities Key Laboratory of Complex System Optimization and Big Data Processing, Yulin Normal University, Yulin, People's Republic of China.
Petro VirychLaboratory of Mechanisms of Drug Resistance, R.E. Kavetsky Institute for Experimental Pathology, Oncology and Radiobiology, Kyiv, Ukraine.
Oleg YeshchenkoPhysics Department, Taras Shevchenko National University of Kyiv, Kyiv, Ukraine.
Pavlo KhortPhysics Department, Taras Shevchenko National University of Kyiv, Kyiv, Ukraine.ORCID 0000-0002-1169-2431
Anton TkachenkoResearch Institute of Experimental and Clinical Medicine, Kharkiv National Medical University, Kharkiv, Ukraine.
Volodymyr ProkopiukResearch Institute of Experimental and Clinical Medicine, Kharkiv National Medical University, Kharkiv, Ukraine.
Nataliia LukianovaLaboratory of Mechanisms of Drug Resistance, R.E. Kavetsky Institute for Experimental Pathology, Oncology and Radiobiology, Kyiv, Ukraine.
Taras ZadvornyiLaboratory of Mechanisms of Drug Resistance, R.E. Kavetsky Institute for Experimental Pathology, Oncology and Radiobiology, Kyiv, Ukraine.
Michel RawisoInstitut Charles Sadron, Strasbourg, France.
Liyao DingGuangxi Universities Key Laboratory of Complex System Optimization and Big Data Processing, Yulin Normal University, Yulin, People's Republic of China.
Nataliya KutsevolChemistry Department, Taras Shevchenko National University of Kyiv, Kyiv, Ukraine.
Taras Shevchenko National University of Kyiv · UAInstitut Charles Sadron · FRR.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology · UAYulin Normal University · CNKharkiv National Medical University · UANational Academy of Sciences of Ukraine · UA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Cancer chemotherapy faces two major challenges - high toxicity of active substances and tumor resistance to drugs. Low toxic nanocarriers in combination with anticancer agents can significantly increase the effectiveness of therapy. Modern advances in nanotechnology make it easy to create materials with the necessary physical and chemical properties. Methods: Two hybrid nanosystems of dextran-polyacrylamide/ zinc oxide nanoparticles (D-PAA/ZnO NPs) were synthesized in aqueous solution with zinc sulphate (D-PAA/ZnO NPs (SO Results: The radius of ZnO NPs (SO Conclusion: The nanosystems were low-toxic to fibroblasts, MAEC. The D-PAA/ZnO NPs nanosystem synthesized using zinc sulphate demonstrates high cytotoxicity due to destruction of various types of cancer cells in vitro and potentially increases adhesion between cells. Thus, our findings indicate the selective cytotoxicity of D-PAA/ZnO NPs against cancer cells and can be potentially used for cancer treatment.

Indexed as

Zinc OxideAcrylic ResinsDextransHumansMalePolyacrylamidesZinc SulfateAcrylic ResinsDextransPolyacrylamidesZinc OxideZinc Sulfatebreast cancercytotoxicitydrug deliverypolymer nanocarrierprostate cancerzinc oxide nanoparticles

Identifiers

PMID37662686
PMCPMC10473965
OpenAlexW4386225906

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.